- Home
- ORKT vs LSTA Comparison
ORKT vs LSTA Comparison
Compare ORKT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKT
- LSTA
- Stock Information
- Founded
- ORKT 2003
- LSTA 1980
- Country
- ORKT Singapore
- LSTA United States
- Employees
- ORKT N/A
- LSTA N/A
- Industry
- ORKT
- LSTA Misc Health and Biotechnology Services
- Sector
- ORKT
- LSTA Health Care
- Exchange
- ORKT NYSE
- LSTA Nasdaq
- Market Cap
- ORKT 34.7M
- LSTA 20.0M
- IPO Year
- ORKT 2024
- LSTA N/A
- Fundamental
- Price
- ORKT $0.77
- LSTA $2.32
- Analyst Decision
- ORKT Strong Buy
- LSTA Strong Buy
- Analyst Count
- ORKT 1
- LSTA 1
- Target Price
- ORKT $5.00
- LSTA $15.00
- AVG Volume (30 Days)
- ORKT 208.5K
- LSTA 17.8K
- Earning Date
- ORKT 10-16-2024
- LSTA 05-08-2025
- Dividend Yield
- ORKT N/A
- LSTA N/A
- EPS Growth
- ORKT N/A
- LSTA N/A
- EPS
- ORKT N/A
- LSTA N/A
- Revenue
- ORKT $3,904,592.00
- LSTA $1,000,000.00
- Revenue This Year
- ORKT N/A
- LSTA N/A
- Revenue Next Year
- ORKT $39.99
- LSTA N/A
- P/E Ratio
- ORKT N/A
- LSTA N/A
- Revenue Growth
- ORKT N/A
- LSTA N/A
- 52 Week Low
- ORKT $0.62
- LSTA $2.05
- 52 Week High
- ORKT $8.00
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- ORKT N/A
- LSTA 42.12
- Support Level
- ORKT N/A
- LSTA $2.07
- Resistance Level
- ORKT N/A
- LSTA $2.62
- Average True Range (ATR)
- ORKT 0.00
- LSTA 0.21
- MACD
- ORKT 0.00
- LSTA 0.01
- Stochastic Oscillator
- ORKT 0.00
- LSTA 47.37
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.